Abcam plc is a global life sciences company specializing in the development, manufacturing and distribution of protein research tools to the scientific community. Its core product portfolio encompasses primary and secondary antibodies, recombinant proteins, peptides and engineered binders, as well as immunoassay kits and related reagents. These products support a broad range of research applications, including Western blotting, immunohistochemistry, flow cytometry, cell culture studies and assay development for both academic and industrial laboratories.
Founded in 1998 and headquartered in Cambridge, England, Abcam has grown through a combination of organic expansion and strategic acquisitions to establish a broad geographic footprint. The company maintains research, manufacturing and customer support facilities across North America, Europe and the Asia-Pacific region, enabling it to serve a diverse base of academic institutions, biotechnology firms and pharmaceutical companies worldwide. Abcam’s emphasis on stringent quality control and scientific validation has made it a trusted partner for researchers seeking reproducible results and novel reagents.
Throughout its history, Abcam has invested heavily in R&D and custom services, offering collaborative assay development and bespoke antibody generation to meet specialized project needs. The company’s management team brings together seasoned industry professionals with expertise in life-science research, global operations and product innovation. By combining a customer-centric approach with ongoing technology enhancements, Abcam aims to accelerate scientific discovery and support the development of new diagnostic and therapeutic solutions.
AI Generated. May Contain Errors.
